Landmark Trial Tests Whether Chemotherapy Can Be Spared in High-Risk Early Breast Cancer
The new phase 3 RxFINE-Low trial will test whether patients with low genomic risk but high anatomic risk early-stage breast ...
The new phase 3 RxFINE-Low trial will test whether patients with low genomic risk but high anatomic risk early-stage breast ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine